Mittlmeier, L. M.
Unterrainer, M.
Todica, A.
Cyran, C. C.
Rodler, S.
Bartenstein, P.
Stief, C. G.
Ilhan, H.
Staehler, M.
Article History
Received: 3 September 2019
Accepted: 22 November 2019
First Online: 11 January 2020
Compliance with ethical standards
:
: Michael Staehler: Consultant: Pfizer, GlaxoSmithKline, Novartis, Bayer, Roche, Aveo, EUSAPharm, Astellas, Ipsen, Exelixis, Pelloton, EISAI, BMS, MSD; honoraria: Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSAPharm, Astellas, Ipsen, Exelixis, Pelloton, EISAI, BMS, MSD; research funding: Pfizer, GlaxoSmithKline, AVEO, BMS, Novartis, Bayer, Roche/Genentech, Immatics, Wilex, Ipsen, Exelixis, EISAI. All other authors declare that they have no relationships or interests that could have direct or potential influence or impart bias on the work.
: The radiopharmaceutical was used on an individual patient basis according to German Pharmaceuticals Act ยง13(2b). Informed written consent was obtained from the patient. The ethical committee of LMU Munich waives additional approval for case reports from clinical practice.